- Home
- SVRA vs BVS Comparison
SVRA vs BVS Comparison
Compare SVRA & BVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SVRA
- BVS
- Stock Information
- Founded
- SVRA 2007
- BVS 2011
- Country
- SVRA United States
- BVS United States
- Employees
- SVRA N/A
- BVS N/A
- Industry
- SVRA Biotechnology: Pharmaceutical Preparations
- BVS Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Sector
- SVRA Health Care
- BVS Health Care
- Exchange
- SVRA Nasdaq
- BVS Nasdaq
- Market Cap
- SVRA 527.2M
- BVS 432.7M
- IPO Year
- SVRA N/A
- BVS 2021
- Fundamental
- Price
- SVRA $3.61
- BVS $7.25
- Analyst Decision
- SVRA Buy
- BVS Strong Buy
- Analyst Count
- SVRA 8
- BVS 5
- Target Price
- SVRA $6.63
- BVS $14.40
- AVG Volume (30 Days)
- SVRA 1.8M
- BVS 388.8K
- Earning Date
- SVRA 11-11-2025
- BVS 11-04-2025
- Dividend Yield
- SVRA N/A
- BVS N/A
- EPS Growth
- SVRA N/A
- BVS N/A
- EPS
- SVRA N/A
- BVS 0.03
- Revenue
- SVRA N/A
- BVS $564,142,000.00
- Revenue This Year
- SVRA N/A
- BVS N/A
- Revenue Next Year
- SVRA N/A
- BVS $6.84
- P/E Ratio
- SVRA N/A
- BVS $261.09
- Revenue Growth
- SVRA N/A
- BVS 5.08
- 52 Week Low
- SVRA $1.89
- BVS $5.81
- 52 Week High
- SVRA $4.70
- BVS $14.38
- Technical
- Relative Strength Index (RSI)
- SVRA 65.26
- BVS 52.47
- Support Level
- SVRA $3.70
- BVS $6.98
- Resistance Level
- SVRA $3.92
- BVS $7.33
- Average True Range (ATR)
- SVRA 0.19
- BVS 0.26
- MACD
- SVRA -0.01
- BVS -0.03
- Stochastic Oscillator
- SVRA 57.94
- BVS 41.86
About SVRA Savara Inc.
Savara Inc is a biopharmaceutical company. It is focused on rare respiratory diseases. The company's program, molgramostim nebulizer solution (molgramostim), is an inhaled granulocyte-macrophage colony-stimulating factor in Phase 3 development for autoimmune pulmonary alveolar proteinosis (aPAP). It has one segment specialty pharmaceuticals within the respiratory system.
About BVS Bioventus Inc.
Bioventus Inc is a medical technology company. The company is engaged in developing and commercializing clinically differentiated treatments that engage and enhance the body's natural healing process. It offers a diverse portfolio of products to serve physicians spanning the orthopedic continuum, including sports medicine, total joint reconstruction, hand and upper extremities, foot and ankle, podiatric surgery, trauma, spine and neurosurgery. Its portfolio of products is grouped into three verticals based on clinical use: Pain Treatments, Surgical Solutions, and Restorative Therapies. Geographical presence is in the United States which derives key revenue, and International markets.